Abandoned study: could a drug fix Chemo-Related kidney injury?
NCT ID NCT05702996
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test the drug eculizumab in cancer patients who developed kidney damage from the chemotherapy drug gemcitabine. The goal was to see if eculizumab could help the kidneys recover. However, the trial was withdrawn before any patients were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eculizumab
- What this could lead to
- If it had worked, this could have pointed toward a treatment for a rare chemotherapy side effect that damages kidneys.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results exist. It was a small pilot study, and eculizumab is expensive with infection risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amiens University Hospital
Amiens, France
-
Rouen University Hospital
Rouen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could interferon be a hidden trigger of blood clot damage after transplant?
- New study aims to detect lung damage earlier in young transplant patients
- New hope for rare blood disorder: experimental drug TGD001 enters human trials
- Could a needle replace a machine? new study aims to simplify lifesaving iTTP treatment
- Promising aHUS drug trial stalls after only 6 patients enrolled
- Promising ITP drug trial pulled before it even started